Methods
The three drugs in the trial were used in the following dosages: Procaine penicillin Intramuscular injection of 2 million units on each of three consecutive days. Mysteclin 'V' Single dose of six capsules, each containing tetracycline 250 mg and nystatin 250,000 u, taken under the supervision of the Clinic staff.
Vibramycin Single oral dose of three capsules, each containing doxycycline 100 mg., taken under supervision. The therapy was allocated in a randomized manner; each patient was given a serial number from 1 to 150 and assigned to one of the three treatment categories by the use of random sampling numbers according to the method described by Hill (1966) .
Fifty patients were allotted in this fashion to each of the three treatment subgroups.
It was not considered ethical to adopt a double-blind trial because, if untoward clinical side-effects occurred the clinician in charge should know immediately what treatment had been given to the patient without consulting the statistical adviser. However, the patient did not know the name of the drug given and the final assessment was a microscopic one, based on the presence or absence of gonococci in a urethral smear; if no urethral discharge was present this was a basic clinical assessment, not liable to personal bias on the part of the clinician. The urethral smear was examined by an experienced laboratory technician who did not know the nature of the treatment and his findings were confirmed by the clinician.
Each patient was assessed for inclusion in the trial by
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(1) The patients were males with acute uncomplicated gonococcal urethritis; (2) Diagnosis was made on the findings of Gram-negative intracellular diplococci in the urethral smear; (3) The patients admitted to the trial had had exposure within the previous 8 days and a discharge which had been present for not more than 5 days. Any history of drug sensitivity precluded the patient from admission to the trial and no patient was admitted unless he was suitable for treatment by each of the three drugs used.
Once the patient was selected for inclusion in the trial, the clinician selected a sealed envelope serially numbered, containing instructions as to which of the randomly selected treatments was to be employed.
The original treatment decided upon was adhered to throughout the trial. If for any reason it was decided to discontinue one drug and substitute another during the course of the trial, that patient was still recorded as having had the first drug, but the result of his treatment was recorded as unknown when the appropriate assessment was being made.
Assessment
The clinician in charge assessed all patients: (i) 24 hours after the cessation of treatment, for the immediate result;
(ii) More than 24 hours and up to 3 weeks after the cessation of treatment, for relapse. Patients who were considered to be re-infected after the 24-hour assessment were still included in the trial from the point of view of the 24-hour assessment, but from the point of view of a later assessment the result was recorded as unknown.
All patients were questioned as to the possibility of having received additional antibiotics from other sources during treatment, e.g. for intercurrent infection. This was denied in all cases.
The following criteria were employed in the assessment: GOOD (a) No gonococci detected in urethral smear; (b) No urethral discharge. POOR Gonococci detected in urethral smear. Extracellular diplococci were detected in three cases, and these were included in this category. The essential criterion was the presence or absence of gonococci in the urethral smear at the appropriate time of assessment. As will be seen from the dosage schedules and times of assessment, patients could be admitted to the trial only on certain days of the week, as the clinic is open only on Monday to Friday. For this reason and because of the strictness of criteria for admission to the trial, the trial lasted from September, 1969, to December, 1970. Seamen and transport drivers were excluded from the trial, as the transient nature of their stay in Melbourne rendered follow-up difficult. Findings Of the 43 patients who received penicillin 37 (86 per cent.), and of fifty patients who received Mysteclin 'V' 25 (50 per cent.), were classified as having a 'good' result.
Applying the x2 test of significance (using 'Yates' correction for small numbers), it was found that the difference between these results was highly significant (X2 = 11-94;P <0-01). The difference between the results was highly significant (Z2 = 11 -24; P < 0 01). This slight difference between the two treatments most likely occurred by chance (X2 = 0-01; P > 0-9). The high dosage of three daily injections of 2 million units of procaine penicillin was used because the same problem of increasing resistance of N. gonorrhoeae to previously curative dosages of penicillin is occurring in Victoria as in almost all countries of the world (Gray, Phillips, and Nicol, 1970; Smithurst, 1970) . Tables II and III It is emphasized that these are minimum failure rates observed at some time during the 3 weeks after cessation of treatment. The results of this trial confirm that, in nonallergic patients, procaine penicillin is still the drug of choice of the three tested.
Mysteclin 'V' and Vibramycin given in single doses yielded too low a rate of cure at the 24-hour assessment to merit their use routinely, but it is suggested that they have their place in the treatment of patients allergic to penicillin who may be transients, e.g. transport drivers and seamen, or in those who are likely to default. In this latter category they may have some effect, however slight, in curbing the spread of disease.
In all patients treated the standard routine was adhered to of blood-testing for syphilis on admission and, wherever possible, again at 3 months from the date of the last sexual exposure.
Since the completion of this trial we have extended the criteria of diagnosis of gonorrhoea and of cure, by the use of cultures performed in the Clinic.
The growth medium used is as follows: The immediate cure rates, as judged by the absence of gonococci from urethral smears 24 hours after treatment, were 86, 50, and 51 per cent. respectively. The difference between the results with penicillin and those with the other regimes was highly significant (P < 0-01).
Further assessment within 3 weeks was partially vitiated by a high default rate. In common with many countries, Australia has experienced increasing resistance of N. gonorrhoeae, and the authors consider that, of the three drugs tested, only penicillin merits routine use. 
